Avid Bioservices Reiterates FY25 Revenue Guidance Of $160M - $168M, Est $162.831M
Portfolio Pulse from Benzinga Newsdesk
Avid Bioservices has reiterated its fiscal year 2025 revenue guidance, projecting revenues between $160 million and $168 million, aligning closely with the estimated $162.831 million.
September 09, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avid Bioservices has reiterated its FY25 revenue guidance of $160M-$168M, which aligns with the market estimate of $162.831M. This reaffirms investor confidence in the company's financial outlook.
The reiteration of revenue guidance within the expected range suggests stability and predictability in Avid Bioservices' financial performance, which is likely to be viewed positively by investors. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100